Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 2

1(20.0%)

Early Phase 1

1(20.0%)

5Total

Phase 1(3)

Phase 2(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06610682Early Phase 1Recruiting

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

Role: collaborator

NCT06385119Phase 1Completed

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

Role: lead

NCT05503797Phase 2Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Role: lead

NCT02428712Phase 1Completed

A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

Role: lead

NCT02012231Phase 1Terminated

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Role: lead

NCT01883388Completed

NovellusDx Cancer Early Detection Blood Test- Clinical Trial

Role: lead

NCT02274025Completed

NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients

Role: lead

NCT01791322Completed

NovellusDx Tissue Collection Protocol

Role: lead

All 8 trials loaded